TEVOGEN BIO
A clinical stage biotech company developing curative and preventative treatments to positively impact global public health. Tevogen is developing T cell immunotherapies in virology, oncology, and neurology, by utilizing patented precision T cell platform technology. Its current intellectual property portfolio includes several breakthrough cell and gene therapy platforms.
TEVOGEN BIO
Industry:
Biopharma Biotechnology Health Care Life Science Medical Oncology Pharmaceutical Product Research Therapeutics
Founded:
2020-01-01
Address:
Warren, New Jersey, United States
Country:
United States
Website Url:
http://www.tevogen.com
Total Employee:
11+
Status:
Active
Contact:
1 877 838-6436
Email Addresses:
[email protected]
Total Funding:
58 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Font Awesome Global Site Tag Organization Schema
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
CSTS Health Care
Biotech, Precision Oncology, Platelet Facilitated Drugs (PFDs)
IACT Health
IACT Health is a research and development firm that performs clinical trials for oncology, cardiology, pulmonology and endocrinology.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Omnia Biosystems
Omnia Biosystems is addressing challenging targets in oncology using artificial intelligence.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
HMP Partners
HMP Partners investment in Series B - Tevogen Bio
HMP Partners
HMP Partners investment in Venture Round - Tevogen Bio
Key Employee Changes
Official Site Inspections
http://www.tevogen.com Semrush global rank: 10.77 M Semrush visits lastest month: 202
- Host name: 192.0.78.163
- IP address: 192.0.78.163
- Location: San Francisco United States
- Latitude: 37.7506
- Longitude: -122.4121
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94110
More informations about "Tevogen Bio"
About - Tevogen
Sadiq Khan, MBA, joins Tevogen to lead its Global Commercial organization. He brings over 30 years of commercial leadership, operations, and alliance management experience. Most recently, Sadiq served as Executive Director …See details»
Home - Tevogen
Dec 26, 2024 Tevogen Bio is a late-stage biotech company harnessing the power of cytotoxic T lymphocytes (CTLs) with its ExacTcell platform. This …See details»
Tevogen Bio Prepares Organizational Readiness to Support …
Nov 26, 2024 Tevogen Bio’s culture, known as C.O.R.E., underpins the company’s mission and fosters a collaborative environment built on Curiosity, Optimism, Respect, and Equality.See details»
Tevogen Bio Prepares Organizational Readiness to Support …
Nov 26, 2024 “Tevogen’s C.O.R.E. values reflect leaderships commitment to embracing diverse perspectives, encouraging a readiness to learn, and creating solutions with a shared purpose,” …See details»
Tevogen Bio - Crunchbase Company Profile & Funding
Tevogen Bio announced an $8 million equity investment and up to $50 million in financing to further advance its operational objectives. Additionally, the company issued a letter to stockholders highlighting recent achievements and growth …See details»
TEVOGEN BIO - LinkedIn
Tevogen Bio’s foundational vision is a healthier world through equitable access to lifesaving innovations. ... HiRO - Harvest Integrated Research OrganizationSee details»
Tevogen Bio Expands Executive Leadership Team to Accelerate …
Apr 5, 2022 Tevogen’s Executive Leadership Team is comprised of experts across cell and gene therapeutic disciplines to accelerate the company’s development and utilization of its next …See details»
Home - Tevogen.ai
Affordability and access for all are at the heart of Tevogen’s vision. In pursuit of that goal, Tevogen.AI is exploring ways that we may deploy artificial intelligence to power target …See details»
Tevogen Bio Prepares Organizational Readiness to Support …
Nov 26, 2024 Warren, N.J., Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically …See details»
Tevogen CEO Reaffirms the Company’s Commitment to Closing …
WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing …See details»
Tevogen Bio Inc. - Tevogen Bio Reports Third Quarter 2024 …
Nov 19, 2024 Improved operating performance by reducing net loss by $52.5 million; reported net loss of $4.3 million and $56.8 million for the nine months ended September 30, for 2024 …See details»
Tevogen Bio - VentureRadar
" Tevogen’s unique T cell therapy approach is a major scientific breakthrough under development and investigation to treat COVID-19, Influenza, almost all Solid Tumors and common …See details»
Tevogen Bio Inc. - Tevogen CEO Expresses Gratitude for …
WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) - Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ) is a clinical-stage specialty immunotherapy biotech …See details»
Tevogen Bio Highlights Promising Trial Data as CEO Leads
Oct 9, 2024 Tevogen is driven by a team of experienced industry leaders and scientists with drug development and global product launch experience. Tevogen’s leadership believes that …See details»
Tevogen CEO Reaffirms the Company’s Commitment to Closing …
WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) - Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing …See details»
Tevogen Bio Inc. - Tevogen Bio Prepares Organizational Readiness …
WARREN, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) - Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing …See details»
Tevogen CEO Reaffirms the Company’s Commitment to Closing …
WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing …See details»
Tevogen Bio Prepares Organizational Readiness to Support
Nov 26, 2024 Ryan Saadi, MD, MPH, Founder and CEO, Tevogen Bio, commented, “I commend Tevogen’s leadership for steering the company’s remarkable growth strategy. With over three …See details»
Tevogen CEO Reaffirms the Company’s Commitment to Closing …
Oct 14, 2024 Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 …See details»
Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of …
Oct 21, 2024 Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the …See details»